Nathan Bhatt

Nathan Bhatt investigates the anti-cancer properties of statins through epidemiological cohort studies and mechanistic research. His large-scale analyses of statin use and cancer incidence have demonstrated risk reductions for colorectal, breast, liver, and other cancers. He investigates the molecular mechanisms by which statin-mediated cholesterol lowering impairs cancer cell proliferation and invasion, including effects on mevalonate pathway products Ras prenylation. His research contributes to the evidence base for potential cancer prevention indications for statins and informs clinical trials.